Advertisement

Langenbeck's Archives of Surgery

, Volume 393, Issue 2, pp 121–126 | Cite as

1,161 patients with adrenal incidentalomas: indications for surgery

  • A. A. Kasperlik-Załuska
  • M. Otto
  • A. Cichocki
  • E. Rosłonowska
  • J. Słowinska-Srzednicka
  • W. Zgliczyński
  • W. Jeske
  • L. Papierska
  • T. Tołłoczko
  • J. Polański
  • R. Słapa
Original Article

Abstract

Background and aims

The aim of this study is to analyze the clinical data and criteria for surgery in a group of over 1,100 patients with adrenal incidentalomas (AI) observed at the Department of Endocrinology.

Patients and methods

The material consisted of 1,161 patients (842 women and 319 men, 10–87 years old) with AI ranging in size from 1.0 to 23.0 cm. The methods included clinical examination, imaging studies, hormonal determinations in the blood and in the urine as well as histological and immunocytochemical investigations in 390 patients treated by surgery.

Results

Basing on these studies, we diagnosed 112 patients with primary malignant adrenal tumors (100 with carcinoma), 45 with metastatic infiltrations, and 1,004 with probable benign AI. Imaging phenotypes (especially high density on computed tomography, CT) were characteristic of malignant and chromaffin tumors. Subclinical adrenal hyperactivity was found in 8% of the patients with pre-Cushing’s syndrome as the most frequent form (6.5%). Chromaffin tumors were detected in 3%.

Conclusions

(1) Indications for surgery include malignant tumors (both primary and metastatic), tumors with subclinical hyperfunction, and chromaffin tumors. High density on CT, >20 HU, appeared to be an important indication for surgery. (2) A slight prevalence of oncological indications over endocrinological indications (14 vs. 11%) was found.

Keywords

Adrenal tumor Adrenal incidentaloma Adrenal cancer Chromaffin tumors 

References

  1. 1.
    Kasperlik-Załuska AA, Migdalska B, Jeske W, Tołłoczko T, Szamowska R, Leowska E, Słowińska-Srzednicka J, Rosłonowska E, Misiorowski W (1992) Incidentally found adrenal tumors: Results of investigation of the pituitary–adrenal axis. Endokr Pol 43:322–329PubMedGoogle Scholar
  2. 2.
    Kasperlik-Załuska AA, Rosłonowska E, Słowińska-Srzednicka J, Migdalska B, Jeske W, Makowska A, Snochowska H (1997) Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol 46:29–37CrossRefGoogle Scholar
  3. 3.
    Angeli A, Osella G, Ali A, Terzolo M (1997) An overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 47:279–283PubMedCrossRefGoogle Scholar
  4. 4.
    Kievit J, Haak HR (2000) Diagnosis and treatment of adrenal incidentaloma: a cost-effectiveness analysis. Endocrinol Metab Clin North Am 29:69–90PubMedCrossRefGoogle Scholar
  5. 5.
    Schteingart DE (2000) Management approaches to adrenal incidentalomas: a view from Ann Arbor, Michigan. Endocrinol Metab Clin North Am 29:127–139PubMedCrossRefGoogle Scholar
  6. 6.
    Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A (2000) A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 85:637–644PubMedCrossRefGoogle Scholar
  7. 7.
    Ambrosi B, Peverelli S, Passini E, Re T, Ferrario R, Colombo P, Sartorio A, Faglia G (1995) Abnormalities of endocrine function in patients with clinically “silent” adrenal masses. Eur J Endocrinol 132:422–428PubMedGoogle Scholar
  8. 8.
    Young WF Jr (2004) Adrenal incidentaloma MTP. ENDO, New Orleans, pp. 7–15Google Scholar
  9. 9.
    Young WF Jr (2000) Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocrinol Metab Clin North Am 29:159–185PubMedCrossRefGoogle Scholar
  10. 10.
    Bernini G, Moretti A, Argenio G, Salvetti A (2002) Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endocrinol 146:523–529PubMedCrossRefGoogle Scholar
  11. 11.
    Kasperlik-Zaluska AA, Slowinska-Srzednicka J (2000) Adrenal response to glucocorticoid treatment. Lancet 355:1458–1459Google Scholar
  12. 12.
    Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667–680PubMedCrossRefGoogle Scholar
  13. 13.
    Kasperlik-Zaluska AA, Cichocki A (2005) Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up. J Experim Therap Oncol 5:125–132Google Scholar
  14. 14.
    Dobbie JW (1969) Adrenocortical nodular hyperplasia: the ageing adrenal. J Pathol 99:1–18PubMedCrossRefGoogle Scholar
  15. 15.
    Griffing GT (1994) A-I-D-S: the new endocrine epidemic. J Clin Endocrinol Metab 79:1530–1531PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • A. A. Kasperlik-Załuska
    • 1
  • M. Otto
    • 2
  • A. Cichocki
    • 3
  • E. Rosłonowska
    • 1
  • J. Słowinska-Srzednicka
    • 1
  • W. Zgliczyński
    • 1
  • W. Jeske
    • 1
  • L. Papierska
    • 1
  • T. Tołłoczko
    • 2
  • J. Polański
    • 4
  • R. Słapa
    • 5
  1. 1.Department of EndocrinologyCenter for Postgraduate Medical EducationWarsawPoland
  2. 2.Department of General, Vascular and Transplant SurgeryMedical University of WarsawWarsawPoland
  3. 3.Department of SurgeryMaria Skłodowska-Curie Memorial Cancer Center and Institute of OncologyWarsawPoland
  4. 4.Department of SurgeryWarsaw University of MedicineWarsawPoland
  5. 5.Department of ImagingWarsaw University of MedicineWarsawPoland

Personalised recommendations